Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , may provide a significant advancement for obesity treatment. Early clinical tests have indicated impressive reductions in abdominal fat , potentially outperforming other weight-loss therapies . However , more assessment is necessary to thoroughly assess its sustain… Read More